Although the patent for pregabalin expired in July 2014, this related to its use in epilepsy and generalised anxiety disorder. As noted in the NICE guideline on neuropathic pain, the Lyrica® (Pfizer) brand of pregabalin has patent protection until July 2017 for its licensed indication of treatment of peripheral and central neuropathic pain. Until this expires generic pregabalin products will not be licensed for this indication and their use for this condition would be off-label and may infringe the patent.